GenSight Biologics
Paris
About GenSight Biologics
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $284.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: epa:SIGHT
- Website: gensight-biologics.com
- Phone: +33 1 76 21 72 20
Industries & Categories
Biotechnology, Genetics, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/gensight-biologics-45397 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.